Chalmers AJ et al. observed the radio-sensitization effect of PARP inhibitors in vitro and animal models with lung cancer, colorectal cancer, head and neck cancer, glioma, cervical cancer, and prostate cancer[29]. Here, PARP1 is linked to central nervous system cancer.